103420-77-5

Basic information

• Product Name: DEVAZEPIDE
• Synonyms: N-[(3S)-2,3-DIHYDRO-1-METHYL-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-1H-INDOLE-2-CARBOXAMIDE;DEVAZEPIDE;EVAZEPIDE, PANOS;(3S)-1-Methyl-3-[(1H-indol-2-yl)carbonylamino]-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one;L-364718;MK-329;(S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide
• CAS NO: 103420-77-5
• Molecular Formula: C₂₅H₂₀N₄O₂
• Molecular Weight: 408.4519
• Mol File: 103420-77-5.mol

Chemical Properties

• Boiling Point: 758.6°Cat760mmHg
• Flash Point: 412.6°C
• Appearance: white to off-white/
• Density: 1.31g/cm³
• Vapor Pressure: 6.56E-23mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: Store at +4°C
• Solubility: DMSO: >5mg/mL
• PKA: 13.25±0.40(Predicted)
• CAS DataBase Reference: DEVAZEPIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DEVAZEPIDE(103420-77-5)
• EPA Substance Registry System: DEVAZEPIDE(103420-77-5)

Safety Data

• Hazard Codes: T+
• Statements: 28
• Safety Statements: 28-36/37-45
• RIDADR: UN 2811 6.1 / PGI
• WGK Germany: 3
• RTECS: NL5994460
• Hazardous Substances Data: 103420-77-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Devazepide is used as a cholecystokinin receptor 1 (CCK1R) antagonist for the treatment of gastrointestinal disorders. It has been utilized in human embryonic kidney 293T cells and human pancreatic slices to block the action of cholecystokinin, a hormone that stimulates the contraction of the gallbladder and the secretion of digestive enzymes.
Used in Research Applications:
In addition to its pharmaceutical applications, Devazepide is also used as an antagonist in research settings. It helps in studying the role of cholecystokinin and its receptors in various biological processes and disorders, contributing to a better understanding of the underlying mechanisms and potential therapeutic targets.

Biochem/physiol Actions

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.

InChI:InChI=1/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1

Upstream product

• 58881-45-1 Indole-2-carbonyl chloride 
• 103343-66-4 (S)-3-amino-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1477-50-5 Indole-2-carboxylic acid 
• 108895-98-3 benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate 
• 108895-97-2 2-α-(benzyloxycarbonyl)glycinyl)amino>benzophenone 
• 103343-47-1 3-amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 
• 161365-75-9 1,3-Dihydro-1-methyl-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 
• 161443-31-8 1,3-Dihydro-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 
• 161365-74-8 benzyl N-[[(2-benzoylphenyl)carbamoyl](1H-1,2,3-benzotriazol-1-yl)methyl]carbamate 

Relevant articles and documents

Benzodiazepine analogs

Benzodiazepine analogs of the formula: STR1 are disclosed which are antagonists of gastrin and cholecystokinin (CCK).

Methods for Drug Discovery: Development of Potent, Selective, Orally Effecive Cholecystokinin Antagonists

3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds.Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.